Targeted partnerships CytoSeek is a discovery-stage biotech focused on cell membrane augmentation to enhance therapies and is actively seeking partnerships with cell therapy companies to bring products to the clinic, presenting a clear collaboration selling point for BD outreach.

Solid tumour focus Current proof-of-principle work targets cancer and solid tumours, offering opportunities to engage oncology cell therapy players and contract research organizations seeking novel approaches to improve CAR-T and related therapies.

AMBP technology The Artificial Membrane-Binding Protein platform provides a unique value proposition for enhancing cell therapies, making CytoSeek a potential vendor for technical differentiation in preclinical development and out-licensing discussions.

Early-stage signals With seed funding secured and leadership appointments in preclinical development, CytoSeek presents a credible, early-stage partner with traction suitable for co-development deals, sponsored research, or milestone-based collaborations.

Pilot engagement Small team size and collaboration history with universities indicate agility and a preference for collaborative, partner-driven programs; ideal for short-term pilot projects to validate AMBP enhancements in specific cell therapies.